Detalhe da pesquisa
1.
Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
J Antimicrob Chemother
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38758191
2.
Efficacy and safety of raltegravir plus lamivudine maintenance therapy.
J Antimicrob Chemother
; 79(2): 255-261, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039097
3.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Clin Infect Dis
; 76(5): 861-870, 2023 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36259527
4.
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Clin Infect Dis
; 77(7): 991-1009, 2023 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207617
5.
Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.
J Antimicrob Chemother
; 78(8): 1955-1962, 2023 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311224
6.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
J Antimicrob Chemother
; 78(9): 2361-2365, 2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37539492
7.
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
J Antimicrob Chemother
; 78(12): 2961-2967, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37875023
8.
Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020.
Euro Surveill
; 28(10)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892474
9.
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
J Antimicrob Chemother
; 77(7): 1974-1979, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512339
10.
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
J Antimicrob Chemother
; 77(4): 1133-1139, 2022 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35040990
11.
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
J Antimicrob Chemother
; 77(7): 1980-1988, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411401
12.
Chemsex Practices in PrEP: Beyond Addiction and Risk Toward a Healthy Sex Life-Baseline Experiences from a Hospital-Based PrEP Program in Barcelona, Spain.
AIDS Behav
; 26(12): 4055-4062, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35732910
13.
Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients.
Infection
; 50(5): 1321-1328, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35562568
14.
Effective Treatment of Lymphogranuloma venereum Proctitis With Azithromycin.
Clin Infect Dis
; 73(4): 614-620, 2021 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462582
15.
Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohort.
J Antimicrob Chemother
; 76(11): 2988-2992, 2021 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34293162
16.
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
J Antimicrob Chemother
; 76(9): 2380-2393, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34120186
17.
Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis.
Gastroenterol Hepatol
; 44(3): 191-197, 2021 Mar.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-33041087
18.
Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study.
J Antimicrob Chemother
; 75(7): 1955-1960, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32134108
19.
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.
J Antimicrob Chemother
; 75(11): 3334-3343, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32737482
20.
Factors associated with the number of drugs in darunavir/cobicistat regimens.
J Antimicrob Chemother
; 75(1): 208-214, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31586414